Lacey John III bought PVCT
June 30, 2026 · Form 4 insider transaction
Lacey John III bought 48,917 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
48,917
Price
$0.00
Total value
N/A
InsiderLacey John III
Role—
SecuritySeries D-1 Convertible Preferred Stock
Transaction codeA: Grant or award
Transaction dateJune 30, 2026
Filing dateJune 30, 2026
Shares owned after228,509
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.